Chiesi Farmaceutici S.p.A, an international, research-focused biopharmaceutical group, and Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, have entered into a global collaboration and license agreement to develop and commercialize seralutinib.   This collaboration combines the strengths of both Chiesi and Gossamer to support ongoing work in pulmonary arterial hypertension...